IN-VIVO AND IN-VIRO MAST CELL STABLIZING ACTIVITY OF ETHYL ACETATE AND METHANOL EXTARCT OF TERMINALIA CHEBULA FRUITS: A THERAPEUTIC APPROACH FOR ASTHMAHTML Full Text
IN-VIVO AND IN-VIRO MAST CELL STABLIZING ACTIVITY OF ETHYL ACETATE AND METHANOL EXTARCT OF TERMINALIA CHEBULA FRUITS: A THERAPEUTIC APPROACH FOR ASTHMA
Sweta Srivastava* and G.P Choudhary
Department of Pharmacognosy, School of Pharmacy, DAVV, Indore, Madhya Pradesh, India.
ABSTRACT: The present investigation deals with the In-vivo and In vitro mast cell stabilizing activity of fruits of Terminalia chebula ethyl acetate and methanol extracts at 500 mg/kg bodyweight. In egg albumin induced degranulation studies, Kitotifen as a standard was found to inhibit degranualtion to an extent of 80.12 %, where as ethyl acetate and methanolic extracts inhibited degaranulation to 58.98% and 44.56% respectively similarly in compound 48/80 induced mast cell degranulation inrats ethyl acetate and methanol extracts of Terminalia chebula and standard Kitotifen showed following percentage inhibition of degranulation of mast cell 40.28%, 51.19 % and 75.12 respectively. In in vivo study ethyl acetate and Methanolic extracts at the dose of 500 mg/kg bodyweight inhibited degranualation of mast cell to a extent of 46.5 % and 37.33% respectively
Terminalia chebula, Kitotifen Methanolic extracts
INTRODUCTION: Asthma may be defined as a condition with recurrent 'reversible' obstruction of the airflow in the airways in response to stimuli which are not in themselves noxious and which do not affect non-asthmatic subjects 1. Asthma is a major global public health problem. The prevalence, and perhaps also severity of the disease is increasing, in particular in urbanized areas around the world. In many countries the prevalence of the asthma is around 5% in the adult population and 10% or higher among children below the age of 10. Although the genetic and environmental causes of asthma remain to be defined more precisely, the recognition of asthma as a chronic inflammatory disorder of the airway has greatly focused a etiological and therapeutic research
Bronchial Asthma according to the GINA guidelines final update November 2006 is clearly defined as: “A chronic inflammatory disorder of the airways in which many cells and cellular elements play a role. The chronic inflammation is associated with airway hyperresponsiveness that leads to recurrent episodes of wheezing, breathlessness, chest tightness and coughing, particularly at night or in the early morning.” These episodes are associated with airflow obstruction within the lung that is often reversible either spontaneously or with treatment 2, 3. Mast cells are constituents of virtually all organs and tissues and are important mediators of inflammatory responses such as allergy and anaphylaxis.
In which histamine remains the best characterized and most potent vasoactive mediator implicated in the acute phase of immediate hypersensitivity upon release 4. Mast cells are broadly distributed throughout mammalian tissues and play a critical role in a wide variety of biologic responses. Typically, mast cells have been considered not only in the association of immediate-type hypersensitivity, but also in late reactions, like inflammatory responses 5. Immediate-type hypersensitivity is mediated by histamine released in response to the antigen crosslinking of immunoglobulin E (IgE) bound to FceRI on the mast cells 6. After activation via the FceRI, the mast cells start the process of degranulation, which results in the releasing of mediators, such as products of arachidonic acid metabolism and an array of inflammatory cytokines 7.
Among the inflammatory substances released from the mast cells, histamine is one of the best characterized and most potent vasoactive mediators implicated in the acute phase of immediate hypersensitivity 8. The morbidity and mortality of asthma haveincreased over the past two decades, particularly inWestern countries 9. In most cases, mild-to moderate asthma is controlled by inhalational steroid. However, long-term steroid therapy is often associated with adverse effects 10. Many side effects of steroids including adrenal suppression and reduction in growth velocity have been reported 11. There is a need for development of additional effective treatments with fewer side effects.
Fruits of Terminalia chebula Retzius (T. chebula Retz.) (Combretaceae), commonly known as black Myroblans in English and Harad in Hindi, indigenous in Pakistan and India among many Asian and African countries, is a popular folk medicine and has been studied for its homeostatic, antitussive, laxative, diuretic and cardiotonic activities 12, 13 . Terminalia chebula is routinely used as traditional medicine by tribals of Tamil Nadu to cure several ailments such as fever, cough, diarrhea, gastroenteritis, skin diseases, candidiasis, urinary tract infection and wound infections 14. Phytochemical investigations of Terminalia Chebula have been reported on presence of tannins, carbohydrates, glycosides, phenols, alkaloids, terpenoids and flavonoids 15.
MATERIALS AND METHODS:
Collection of Plant Material:
The fruits of Terminalia chebula was collected from the local market, Indore. The plant material was identified at Department of Botany, Holkar Science College, Indore, and their voucher specimens were deposited in the Department of Pharmacognosy, School of Pharmacy, Devi Ahilya Vishwavidhyalaya, Indore.
Preparation of Plant Extracts:
The air dried plant material was reduced to coarse powder and subjected to successive solvent extraction with solvents Pet. Ether, Chloroform, Ethyl acetate and Methanol in soxhlet extractor. After the complete extraction, the solvent was distilled off and concentrated on a water bath to a dry residue. The extracts were concentrated by distilling of the solvent and then evaporated to dryness on water bath. Ethyl acetate and methanolic group showed the presence of maximum phytochemical constitutents that’s why only these two groups for undertaken for further study 16, 17.
Animals-Male Wister rats (200-250g) were obtained from the experimental animal house. The animals were housed in polypropylene cages under standard conditions (12 h light; 12 h dark cycle; 25± 5oC; 35-60% humidity). They were fed with standard pellet diet (Pranav Agro Ltd, Dehradun) and water ad libitum. The experimental protocol was approved by the Institutional Animal Ethical Committee (IAEC/PCP/2014/49).
Evaluation of in vitro mast cell stabilizing activity
Sensitized mast cell were obtained from animals sensitized with egg albumin. The doses to the animal groups (Six animal in each group); Group 1: Control, Group 2: Kitofen (Standard), Group 3: Ethyl acetate extract of Terminalia chebula, 500 mg/kg bodyweight; Group 4: methanolic extract of Terminalia chebula 500 mg/kg bodyweight being given on the 1st, 3rd and 5th day. The sensitized mast cells were degranulated using egg albumin (1mg/ml) on the 10th day of sensitization. The normal mast cell were degranulated using compound 48/80 (100mcg/ml). To the cell suspension of mast cells 0.1 ml of the peritoneal mast cell suspension, 0.1ml of the test agent in the saline was added and incubated in a constant temperature water bath (37oc) for 15 minutes. Then 0.1 ml of degranulaing agent (Egg albumin 1 mg/ml and compound 48/80 100mcg/ml) was added and further incubated for a period of 10 minutes. The cell were then stained with 0.1% toluidine blue for 5-10 min and the tissue was then washed in acetone and then xylene (2 changes each) for 5 min each wash. The stained cells were viewed through a digital light microscope at 100x magnification and 100 mast cells were counted. The number of intact and fragmented or disrupted mast cells was noted.
A mast cell was considered disrupted if four or five granules were found around the mast cells. The number of fragmented or disrupted mast cells as well as of the intact mast cells were counted 18.
Group 1: Control, Group 2 : Kitofen (Standard), Group 3 : Ethyl acetate extract of Terminalia chebula, 500 mg/kg bodyweight; Group 4: methanolic extract of Terminalia chebula 500 mg/kg bodyweight) rats were sensitized by injecting subcutaneously 0.5 ml of horse serum along with 0.5 ml tripple antigen containing 20,000 million Bordetella pertussis organism . Rats of group 1 received water (vehicle) and served as control Rats of group 3 and 4 were administered herbal extracts p.o respectively, once a day for 14 days. Group 2 rats received 10 mg/kg of Prednisolone (standard) orally for same duration. On day 14, the rats were sacrificed two hours after treatment and the intestinal mesentery was taken for the study on mast cells. Mesenteries of sacrificed rats along intestinal pieces were kept in Ringer –Locke solution.
The mesenteric pieces were challenged with horse serum for 10 minutes after which the mast cell were stained and examined microscopically for the number of intact and degranulated mast cell. Pieces of intestinal mesentry will be mounted on slide which will be air dried and then stained with 1% toludine blue, at room temperature for 5 min. Mast cell will be readily identified by their metachromatic cytoplasmic granules under light microscope 19.
RESULT: All experimental data were expressed as mean ± SEM. (Table) Statistical analysis was carried out by using one way ANOVA followed by Dunnett‘s test. In present study the rats of unsensitized group ie control group showed 12.33±1.03% of degranualted mast cell where as standard drug Prednisone found to inhibit degranulation of mast cell by 30.16±2.13%. The ethyl acetate and Methanolic extracts at the dose of 500mg/kg bodyweight inhibited degranualation of mast cell to a extent 46.5±2.16 % and 37.33±2.73 % respectively.
TABLE 1: IN- VIVO MAST CELL STABLIZING ACTIVITY OF TERMINALIA CHEBULA EXTRACT
|Treatment||Doses (mg/kg body weight)||Route of Administartion||Granulated mast cell||Non -Granulated mast cell|
|Control(TWEEN 80, 1)*||Oral||85.83±1.72||12.33±1.03|
|Control(TWEEN 80,1) sensitize||Oral||23.66±3.32||82.5±3.06|
|Ethyl acetate Terminalia chebula||500||Oral||68.83±1.72||46.5±2.16|
|Methanolic Terminalia chebula||500||Oral||65.33±2.33||37.33±2.73|
*: p< 0.05 Vs control n= number of animals
TABLE 2: EFFECT OF TERMINALIA CHEBULA EXTRACTS ON EGG ALBUMIN INDUCED MAST CELL DEGRANULATION IN RATS.
|TreatmentN=6||Dose (mg/kg)||Number of mast cells||Percent inhibition|
|Control||9 ± 1.3|
|Ketotifen||10 mcg / ml||88 ± 1.5*||80.12± 1.02|
|Ethyl acetate extract of Terminalia chebula||500||60 ± 1.03*||58.98± 1.04|
|Methanol. Extract of Terminalia chebula||500||46 ± 0.17*||44.56± 1.01|
*: p< 0.05 Vs control n= number of animals
TABLE 3: EFFECT OF TERMINALIA CHEBULA EXTRACTS ON COMPOUND 48/80 INDUCED MAST CELL DEGRANULATION IN RATS.
|Treatment N=6||Dose (mg/Kg)||Number of mast cells||Percent inhibition|
|Control||6 ± 0.11|
|Ketotifen||10 mcg / ml||78 ± 1.26*||75.12 ± 1.08|
|Ethyl acetate extract of Terminalia chebula||500||52 ± 1.13*||51.19 ± 1.27|
|Methanol. Extract of Terminalia chebula||500||41 ± 0.13*||40.22 ± 1.45|
*: p< 0.05 Vs control n= number of animals.
DISCUSSION: The aim of present investigation was to evaluate the asthamatic activity by mast cell stabilizers model. In mast cell stabilising study, the efficacy of the drug to prevent mast cell degranulation is observed. Upon injecting allergen horse serum to the test animals, IgE production is enhanced leading to increase in histamine. This leads to an increase in Inositol triphosphate leading to calcium ion influx. This causes degranulation of mast cells. The control group animals showed maximum mast cell degranulation as observed from histopathology slides. Upon administration of extracts, the degranulation was decreased. This might be due to mast cell stabilizing potential against antigen-antibody reaction or due to suppression of IgE antibody production, responsible for degranulation 20.
Mast cells are known to be the primary responders in allergic reactions, most of which are triggered by cross-linking of a high-affinity IgE receptor (FC RI).Allergic manifestations include allergic rhinitis, anaphylaxis, purities and asthma - the diseases associated with inflammatory conditions. In mast cell stabilising study, the efficacy of the drug to prevent mast cell degranulation was observed 21.
Methanolic and ethyl acetate extracts of Terminalia chebula markedly protected the sensitized mast cells. However, the effect was less than that observed with the standard drug used. The pathological mechanism involved in Type-I allergy has been explained as the degranulation of mast cells and basophils, followed by the release of mediators such as histamine, leukotrienes and prostaglandins from these cells.
- Rang HP, Dale MM, Ritter JM, Moore PK. Pharmacology, 5th Ed. Churchill Livingstone, New York, 2003; 217-241.
- Djukanovic R, Roche WR, Wilson JW. Mucosal inflammation in asthma. Am J Resp Crit Care Med 1990; 142: 434-457.
- Uvnas B. Mast cells and Histamine release. Indian J Pharmacol. 1969; 1(2): 23-25.
- Eid N, Morton R, Olds B, Clark P, Sheikh S and Looney S. Decreased morning serum cortisol levels in children with asthma treated with inhaled fluticasone propionate. Pediatrics. 2002; 109: 217-221.
- Visser M J. Side-effects of fluticasone in asthmatic children: no effects after dose reduction. Eur. Respir. J. 2004; 24(3): 420-5.
- Kemp SF, Lockey RF. Anaphylaxis: a review of causes and mechanisms. J Allergy Clin Immunol. 2002; 110: 341–348.
- Metzger H, Alcaraz G, Hohman R, Kinet JP, Pribluda V, Quarto R. The receptor with high affinity for immunoglobulin E. Annu Rev Immunol. 1986; 4: 419–470.
- Galli SJ, Kalesnikoff J, Grimbaldeston MA, Piliponsky AM, Williams CM, Tsai M. Mast cells as ‘‘tunable’’ effector and immunoregulatory cells: recent advances. Annu Rev Immunol. 2005; 23: 749–786.
- Petersen LJ, Mosbech H, Skov PS. Allergen-induced histamine release in intact human skin in vivo assessed by skin microdialysis technique: characterization of factors influencing histamine releasability. J Allergy Clin Immunol: 1996; 97: 672–679.
- Global Initiative for Asthma, Global Strategy for Asthma Management and Prevention, update 2010; 2.
- Aggarwal A N, Chaudhry K, Chhabra S K, D’Souza GA, Gupta D, Jindal S K, Katiyar S K, Kumar R, Shah B, Vijayan V K, Prevalence and risk factors for bronchial asthma in Indian adults: a multicentre study, The Indian Journal of Chest Diseases & Allied Sciences. 2008; 48: 13-22.
- Srivastava S, Choudhary G P. Evaluation of Antitussive and Mast cell stabilizing Activity of Piper longum fruits extracts. A therapeutic approach for treatment of Asthma. Am. J. Pharm Health Res. 2014: 2(8): 1-14.
- Fabry W, Okemo P O, Ansorg R. Antibacterial activity of East African medicinal plants. Journal of Ethnopharmacology, 60, pp 79-/84.
- Sangeetha R, Nirmala P. Antimicrobial Activity of Terminalia chebula Against Urinary Tract Pathogens. International Journal of Institutional Pharmacy and Life Sciences. 2012; 2(4): 24-39.
- Srivastava S, Choudhary G P.Evaluation of Antitussive Activity of Fruits o f Terminalia chebula on Cough Reflex Induced by Different Cough Retz Induced Models In Mice. IJPLS. 2014; 5(4): 3497-3501.
- Choudhary G P.; In Vitro Mast Cell Stabilization Activity of Onosma Bracteatum Wall; International Journal of Pharma and Bio Sciences V1 (2). 2010: 1-6.
- Samiulla D S, Prashanth D, Amit A.; Mast cell stabilising activity of Bacopa monnieri; Fitoterapia. 2001; 72: 284-285.
- Mitra S K, Gopumadhavan S, Mohamed Rafiq, Venkataranganna MV:Antihistaminic and antianaphylactic activity of HK-07, a herbal formulation.H.K-07 Indian journal of pharmacology. 2005; 37(5): 300-303.
- Mitra S.K, Gopumadhavan S, Venkataranganna M.V. Antiasthmatic and antianaphylactic effect of E-721, a herbal formulation. Indian journal of pharmacology. 1999; 31:133-137.
- Agarwal SS, Paridhavi M.. Herbal Drug Technology, 2nd Ed., Universities Press Pvt Ltd, India. 2007; 341-380.
- Khandelwal K R; Practical Pharmacognosy; Nirali Prakashan Tenth edition. 2003 ; 158.
How to cite this article:
Srivastava S and Choudhary GP: In-vivo and In-viro Mast Cell Stablizing Activity of Ethyl Acetate and Methanol Extarct of Terminalia Chebula Fruits: A Therapeutic Approach for Asthma. Int J Pharmacognosy 2016; 3(6): 246-50:.doi link: http://dx.doi.org/10.13040/IJPSR.0975-8232.IJP.3(6).246-50.
This Journal licensed under a Creative Commons Attribution-Non-commercial-Share Alike 3.0 Unported License.
Sweta Srivastava* and G.P Choudhary
Department of Pharmacognosy, School of Pharmacy, DAVV, Indore, Madhya Pradesh, India.
24 April, 2016
25 June, 2016
28 June, 2016
30 June, 2016